Forecasting outcomes, costs and trade-offs

When a healthcare innovation affects the trajectory of a disease over time, PHE uses innovative analysis and modeling to understand the health and economic impacts of these changing disease dynamics. These analyses may consider important complexities such as:

  • The downstream implications and value of early treatment of HIV infection in reducing transmission of HIV to others
  • The potential population-level benefits of precision medicine policies that encourage disease prevention
  • The costs of chronic lymphocytic leukemia according to disease and remission status
  • The long-term impact to society of policies that encourage broad treatment of HCV, lowering costs associated with advanced disease, and reducing transmission of the disease to others in the population

One of PHE’s primary disease modeling tools is The Health Economics Medical Innovation Simulation (THEMIS), a proprietary microsimulation that tracks individuals 25 and older over their remaining lives to project health and economic outcomes based upon real-world longitudinal data. PHE has also employed custom-built models when appropriate to study the impacts of nuanced disease dynamics on outcomes.

PHE’s studies on disease outcomes and costs typically use modeling approaches, such as PHE’s proprietary microsimulation, THEMIS. Learn more about these models below.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.